CTLA4 and acute kidney injury: One review found that the average onset of AKI was shorter in patients treated with the anti-CTLA-4 agent ipilimumab (6 to 12 weeks), as compared to anti-PD-1 agents pembrolizumab (1 to 12 months) and nivolumab (6 to 12 months) (23).